Hematologic response
| Response . | Imatinib resistant . | Imatinib intolerant . | Total . | |||
|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | No. . | % . | |
| Cumulative response | ||||||
| Evaluable patients | 199 | 88 | 287 | |||
| Complete response | 172 | 86 | 75 | 85 | 247 | 86 |
| Cumulative response among patients with no baseline complete hematologic response | ||||||
| Evaluable patients | 100 | 41 | 141 | |||
| Complete response | 76 | 76 | 34 | 83 | 110 | 78 |
| Reason for exclusion from analysis | ||||||
| No baseline assessment | 1 | 0 | 1 | |||
| Response . | Imatinib resistant . | Imatinib intolerant . | Total . | |||
|---|---|---|---|---|---|---|
| No. . | % . | No. . | % . | No. . | % . | |
| Cumulative response | ||||||
| Evaluable patients | 199 | 88 | 287 | |||
| Complete response | 172 | 86 | 75 | 85 | 247 | 86 |
| Cumulative response among patients with no baseline complete hematologic response | ||||||
| Evaluable patients | 100 | 41 | 141 | |||
| Complete response | 76 | 76 | 34 | 83 | 110 | 78 |
| Reason for exclusion from analysis | ||||||
| No baseline assessment | 1 | 0 | 1 | |||